These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38712561)

  • 21. A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany.
    Jakobs F; Wingen-Heimann SM; Jeck J; Kron A; Cornely OA; Kron F
    BMC Health Serv Res; 2021 Sep; 21(1):939. PubMed ID: 34496836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Costs Associated with the Treatment of Clostridioides Difficile Infections.
    Sierocka A; Kiersnowska Z; Lemiech-Mirowska E; Marczak M
    Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34300098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
    Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
    Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer.
    Esmaily-Fard A; Tverdek FP; Crowther DM; Ghantoji SS; Adachi JA; Chemaly RF
    Pharmacotherapy; 2014 Nov; 34(11):1220-5. PubMed ID: 25164587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
    Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
    Chen J; Gong CL; Hitchcock MM; Holubar M; Deresinski S; Hay JW
    Clin Microbiol Infect; 2021 Oct; 27(10):1448-1454. PubMed ID: 33878506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US.
    Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
    Adv Ther; 2023 Jun; 40(6):2801-2819. PubMed ID: 37093360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for
    Dubberke ER; Puckett JT; Obi EN; Kamal-Bahl S; Desai K; Stuart B; Doshi JA
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac435. PubMed ID: 36267250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.
    Stabholz Y; Paul M
    Clin Microbiol Infect; 2024 Jan; 30(1):51-58. PubMed ID: 37690610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective, observational study of fidaxomicin use for
    Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
    J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations.
    Goldenberg SD; Brown S; Edwards L; Gnanarajah D; Howard P; Jenkins D; Nayar D; Pasztor M; Oliver S; Planche T; Sandoe JA; Wade P; Whitney L
    Eur J Clin Microbiol Infect Dis; 2016 Feb; 35(2):251-9. PubMed ID: 26661400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland.
    van Engen A; Casamayor M; Loftus F; Coen M; Garnham A; Watt M; Lacey L
    J Health Econ Outcomes Res; 2015; 2(2):192-206. PubMed ID: 37663580
    [No Abstract]   [Full Text] [Related]  

  • 34. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defining optimal treatment for recurrent Clostridioides difficile infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrence.
    Johnson S; Gerding DN; Li X; Reda DJ; Donskey CJ; Gupta K; Goetz MB; Climo MW; Gordin FM; Ringer R; Johnson N; Johnson M; Calais LA; Goldberg AM; Ge L; Haegerich T
    Contemp Clin Trials; 2022 May; 116():106756. PubMed ID: 35398532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
    Burton HE; Mitchell SA; Watt M
    Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
    Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
    van Prehn J; Reigadas E; Vogelzang EH; Bouza E; Hristea A; Guery B; Krutova M; Norén T; Allerberger F; Coia JE; Goorhuis A; van Rossen TM; Ooijevaar RE; Burns K; Scharvik Olesen BR; Tschudin-Sutter S; Wilcox MH; Vehreschild MJGT; Fitzpatrick F; Kuijper EJ;
    Clin Microbiol Infect; 2021 Dec; 27 Suppl 2():S1-S21. PubMed ID: 34678515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis.
    Konijeti GG; Sauk J; Shrime MG; Gupta M; Ananthakrishnan AN
    Clin Infect Dis; 2014 Jun; 58(11):1507-14. PubMed ID: 24692533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.